SPORE in Lymphoma

淋巴瘤中的孢子

• 批准号: 7681128
• 负责人: RICHARD I FISHER
• 金额: $ 230万
• 依托单位: UNIVERSITY OF ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-01 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7681128
• 关键词: SPORE; Lymphoma

DESCRIPTION (provided by applicant): This Lymphoma SPORE application from the James P. Wilmot Cancer Center (JPWCC), University of Rochester, and the Arizona Cancer Center (ACC), University of Arizona provides a broad based, translational research program studying several major unresolved issues in the lymphoma biology. Specifically the projects will focus on several novel, targeted therapeutic agents either in development or approved for the treatment of three of the most common non-Hodgkin's lymphomas, namely diffuse large B-cell, follicular and mantle cell lymphoma. We will initially seek to elucidate mechanisms of action and/or resistance both in vitro, and in carefully developed model systems; then pilot clinical trials with an emphasis on correlative studies will be designed and conducted to validate these mechanisms. Investigators at the JPWCC and the ACC, long-time collaborators, lead each of the programs. The clinical and pathologic resources of the Lymphoma Committee of the Southwest Oncology Group are also integrated into this program. Projects include: Research Project 1: Targeting Aurora Kinase in Aggressive B-cell non-Hodgkin's Lymphoma, Project 2: Optimizing Redox Modulation as a Therapeutic Strategy for NHL. Project 3: Potentiating Proteasome Inhibitor Activity in NHL. Project 4: Characterization of Lymphoma-lnitiating Cells.

描述（由申请人提供）：本淋巴瘤孢子申请来自罗切斯特大学James P. Wilmot癌症中心（JPWCC）和亚利桑那大学亚利桑那癌症中心（ACC），提供了一个基础广泛的转化研究项目，研究淋巴瘤生物学中几个主要的未解决的问题。具体来说，这些项目将专注于几种正在开发或已批准的新型靶向治疗药物，用于治疗三种最常见的非霍奇金淋巴瘤，即弥漫性大b细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤。我们将首先在体外和精心开发的模型系统中寻求阐明作用和/或耐药性的机制；然后，将设计和实施以相关研究为重点的试点临床试验，以验证这些机制。JPWCC和ACC的调查人员是长期合作伙伴，他们领导着每个项目。西南肿瘤学会淋巴瘤专业委员会的临床和病理资源也被纳入本项目。项目包括: